



The INVOS™ Cerebral/Somatic Oximeter  
The full physiologic perspective, when it absolutely matters

 **COVIDIEN**  
*positive results for life™*

*Everything in Perspective*

# The Clinical Standard

When it comes to clinical evidence, the INVOS™ cerebral/somatic oximeter stands alone. Clinicians around the world have come to rely on the INVOS™ system to guide their decisions in critical situations. Trust has been earned through both clinical performance and by extensive published research. For those reasons, the INVOS system is the clinical standard in regional oximetry.

## The INVOS System – A Clear Choice Supported by Clinical Data

- The only cerebral oximeter on the market to be tested and validated under varying levels of CO<sub>2</sub> to ensure measurement sensitivity during changing levels of blood volume under the sensor.<sup>1</sup>

*Refer to figure 1*

- Provides reliable, real-time data (what some manufacturers call “absolute”) in patients > 2.5 kg.
- The only cerebral/somatic oximeter with rigorous, peer-reviewed clinical investigations demonstrating ability to improve patient outcomes.<sup>3,4</sup>

*Refer to figure 2*

- More than 1,000 clinical studies (more than 600 which are peer-reviewed) show the INVOS system as the clinical standard.
- Three published, randomized, controlled trials have established the clinical value of the INVOS system to aid clinicians in improving patient outcomes.
- The only device with a claim for improved outcomes after surgery.<sup>3,4,6</sup>

Figure 1: The INVOS system’s validation is extensive

	Validation: FiO <sub>2</sub> normoxia and hypoxia	Validation: CO <sub>2</sub> normocarbida and hypercarbia	Validation: Published emitter sensor spacing	Validation: Published sensitivity to changes in oxygenation
<b>INVOS™ 5100C Monitor</b>	Yes <sup>1</sup>	Yes <sup>1</sup>	Yes <sup>2</sup>	Yes <sup>1</sup>

Figure 2: Documented clinical performance<sup>5</sup>

	All articles, abstracts, and posters	Published and peer-reviewed articles	Outcome correlation (peer-reviewed)	Outcome improvement (peer-reviewed)
<b>INVOS™ System</b>	1,000+	600+	30+	3

June 2013


# The INVOS™ System Difference

Before you decide which NIRS technology to use, consider this: All NIRS technology is not the same. Clinical evidence for one technology does not necessarily apply to another. Each cerebral oximeter uses unique methodologies, algorithms and sensor design to analyze the oxy-hemoglobin saturation in tissue. The clinical evidence supporting the INVOS system is specific to INVOS™ technology and does not reflect the performance of competitive products.

## The INVOS System Offers a Measure of $rSO_2$ Not Available With Other Oximeters

Only the INVOS system has been proven to be clinically effective in providing clinicians with physiologic insights into a patient's status to make care management decisions that contribute to improving patient outcomes.

- It is the **ONLY** cerebral oximeter on the market that is validated via a published hypoxia study under different levels of  $PaCO_2$ .<sup>1</sup>
- Using an optimized emitter spacing configuration, the INVOS system demonstrates sensitivity to subtle changes in saturation and cerebral blood flow.



### **Another manufacturer's disclaimer – accurate when patients are “normal”**

Another manufacturer states that their device is designed to determine regional hemoglobin oxygen saturation of blood underneath the sensor.<sup>7</sup> They also state that the performance and accuracy of the device can be degraded or impacted if the patient's  $CO_2$  levels are non-normocapnic (non-normal) or if there are other conditions that affect blood volume.<sup>7</sup> Do your patients always have “normal”  $CO_2$  levels?



# The Whole Picture

Other companies promote the “absolute intervention threshold” or what is sometimes called “absolute accuracy” capability of their oximeters. **There’s more to the picture.**

- Exactly what does “absolute intervention threshold” or “absolute accuracy” mean? At this time, there are no regulations or standards that define the parameters for these marketing terms.
- Current cerebral oximeter technology does not allow for “absolute” measurements. The only real way to measure “absolute” cerebral oxygenation levels is to sample blood from a patient’s brain, which oximeters don’t do.
- “Absolute intervention thresholds” or “absolute accuracy” alone are not definitive of a patient’s full physiologic condition. Each patient is unique and there is a wide range of “normal” values for cerebral venous oxygenation, which is contrary to an absolute measurement threshold for intervention.<sup>8</sup>

The INVOS™ system provides clinicians with vital physiological data, based on each patient’s “normal”, to allow the clinician to customize care for that individual.

## Baselines Matter – Customize Care for Each Patient’s “Normal”

What is “normal”? When it comes to an individual patient’s measurement, “normal” can cover a wide range. That’s why establishing an individualized baseline is so critical. It shows you where each patient’s physiologic “normal” range begins and ends so that you can customize care for that individual. The INVOS™ cerebral/somatic oximeter features a baseline setting that provides additional dimension and value to the rSO<sub>2</sub> measurement. Combine this baseline with continuous monitoring and the result is critical, early warnings of developing pathology and deteriorating patient condition.<sup>8,9,10,11</sup> This is the kind of timely information you need – and can rely on – during surgery.

Unlike pulse oximetry, which measures arterial oxygen, the INVOS system measures rSO<sub>2</sub>, a reflection of cerebral venous saturation. This is an important distinction, because cerebral saturation has a much wider range of normal values (45% to 75%) than arterial saturation, which has a very narrow range. With this wider range of cerebral saturation, clinicians will make more informed decisions about intervention during surgery, based on the most individualized “normal” for each patient. The end result? Studies have demonstrated that intervening based upon a relative drop of rSO<sub>2</sub> from baseline improved patient outcomes.<sup>3,4</sup>





# There's No Better Choice for Better Patient Outcomes

The INVOS™ system is the only regional oximeter with improved patient outcomes labeling. It stands alone as the best (and tested) choice to improve patient outcomes after cardiac surgery. And for patients, that's big news.

## Reduce Complications, Improve Outcomes

### **Reduced major organ morbidity or mortality (MOMM)<sup>3</sup>**

A randomized, controlled clinical study demonstrated that monitoring cerebral rSO<sub>2</sub> in coronary artery bypass patients avoids profound cerebral desaturation and is associated with significantly fewer incidences of major organ dysfunction.<sup>3</sup>

- Only 3% of the INVOS system group experienced MOMM compared to 11% in the control group and compared to 13.4% from the Society of Thoracic Surgeons database.

### **Reduced length of ICU stay<sup>3</sup>**

Also clinically demonstrated, ICU length of stay for the INVOS system group was significantly shorter.<sup>3</sup>

- Mean 0.62 day reduction in length of stay, p<0.029.

### **Reduced stroke and need for prolonged ventilation<sup>6</sup>**

INVOS system use on cardiac surgery patients reduced permanent stroke and reduced total time needed for mechanical ventilation.<sup>6</sup>

- Incidence of permanent stroke <1% in the INVOS system group compared with 2% in the control group, p <0.044.<sup>6</sup>
  - The study group had greater comorbidities than those in the control group
  - Rated using New York Heart Association (NYHA) classifications
- Median ventilator time of four hours vs. five hours in the control group, p<0.0016. A significantly greater proportion of the patients in the control group required prolonged ventilation, 10.6% vs. 6.8%, p<0.0014.<sup>6</sup>

# Everything in Perspective, When it Absolutely Matters

The INVOS™ system is the clinical standard in regional oximetry monitoring. It's also the most widely used regional oximeter in the world<sup>12</sup> – for a reason. The INVOS system has been proven by extensive clinical investigations to improve patient outcomes.<sup>3-4</sup> Unique INVOS™ technology enables clinicians to detect subtle, physiologic changes in saturation and cerebral perfusion in order to make timely, critical lifesaving decisions for improved patient outcomes.





## Clinical Benchmark, Market Leader

The Covidien INVOS™ system has long been the clinical benchmark and market leader<sup>12</sup> in NIRS technology. It's no coincidence. Getting essential physiologic data about the patient's well-being, with actionable insights and trends, into your hands at the right moment helps you make lifesaving decisions.

### **INVOS system benefits:**

- Continuous rSO<sub>2</sub> monitoring in multiple patient types<sup>4,13,14,15,16,17</sup>
- Timely rSO<sub>2</sub> data to trigger interventions<sup>3,15,18,19</sup>
- Improved patient outcomes<sup>3,6,20</sup>
- Reduced hospital resource requirements<sup>3,6</sup>

For more information about the INVOS system  
contact your local representative or visit  
[covidien.com/rms/products/cerebral-somatic-oximetry](https://www.covidien.com/rms/products/cerebral-somatic-oximetry).



#### References

1. Kim M, Ward D, Cartwright C, et al. Estimation of jugular venous O<sub>2</sub> saturation from cerebral oximetry or arterial O<sub>2</sub> saturation during isocapnic hypoxia. *J Clin Monit Comput.* 2000;16(3):191-99.
2. Hongo K, Kobayashi S, Okudera H, Hokama M, Nakagawa F. Noninvasive cerebral optical spectroscopy: Depth-resolved measurements of cerebral haemodynamics using indocyanine green. *Neural Res.* 1995;17(2):89-93.
3. Murkin JM, Adams SJ, Novick RJ, et al. Monitoring brain oxygen saturation during coronary bypass surgery: a randomized, prospective study. *Anesth Analg.* 2007;104(1):51-58.
4. Casati A, Fanelli G, Pietropaoli P, et al. Continuous monitoring of cerebral oxygen saturation in elderly patients undergoing major abdominal surgery minimizes brain exposure to potential hypoxia. *Anesth Analg.* 2005;101(3):740-747.
5. Covidien. Data on file.
6. Goldman S, Sutter F, Ferdinand F, Trace C. Optimizing intraoperative cerebral oxygen delivery using noninvasive cerebral oximetry decreases the incidence of stroke for cardiac surgical patients. *Heart Surg Forum.* 2004;7(5):E376-381.
7. NONIN Operator's Manual Model 7600, Page 3, Cautions.
8. Aron JH, Fink GW, Swartz MF, et al. Cerebral oxygen desaturation after cardiopulmonary bypass in a patient with raynaud's phenomenon detected by near-infrared cerebral oximetry. *Anesth Analg.* 2007;104(5):1034-1036.
9. Alie RF, Hymes W, Kooperman S. Intra-aortic balloon counterpulsation in an off-pump procedure shows improved cerebral perfusion by near-infrared spectroscopy. *J Cardiothorac Vasc Anesth.* 2010;24(2):300-302.
10. Joshi RK, Motta P, Horibe M, Mossad E. Monitoring cerebral oxygenation in a pediatric patient undergoing surgery for vascular ring. *Ped Anesth.* 2006;16:178-181.
11. Schwartz JM, Vricella LA, Jeffries MA, Heitmiller ES. Cerebral oximetry guides treatment during Blalock-Taussig shunt procedure. *J Cardiothorac Vasc Anesth.* 2008;22(1):95-97.
12. Market share based on data provided by Millennium Research Group.
13. INVOS™ 5100C Operator's Manual.
14. Vasdekis SN, Tsivgoulis G, Athanasiadis D, et al. Cerebrovascular reactivity assessment in patients with carotid Artery Disease: A combined TCD and NIRS study. *J Neuroimaging.* 2012;22(3):261-265.
15. Rubio A, Hakami L, Münch F, Tandler R, Harig F, Weyand M. Noninvasive control during low-flow antegrade selective cerebral perfusion on adults and infants in the aortic arch surgery. *J Card Surg.* 2008;23(5):474-479.
16. Van der Laan ME, Verhagen EA, Bos AF, Berger RMF, Kooi EMW. Effect of balloon atrial septostomy on cerebral oxygenation in neonates with transposition of the great arteries. *Pediatr Res.* 2013;73(1):62-67.
17. Uchino H, Nakamura T, Kuroda S, Houkin K, Murata J, Saito H. Intraoperative dual monitoring during carotid endarterectomy using motor evoked potentials and near-infrared spectroscopy. *World Neurosurg.* 2012;78(6):651-657.
18. Deshamps A, Lambert J, Couture P, et al. Reversal of decreases in cerebral saturation in high-risk cardiac surgery. *J Cardiothorac Vasc Anesth.* 2013;27(6):1260-1266.
19. Leontyev S, Borger MA, Legare J-F, et al. Iatrogenic type a aortic dissection during cardiac procedures: early and late outcome in 48 patients. *Eur J Cardio-Thorac.* 2012;41(3):641-646.
20. Slater JP, Guarino T, Stack J, et al. Cerebral oxygen desaturation predicts cognitive decline and longer hospital stay after cardiac surgery. *Ann Thorac Surg.* 2009;87(1):35-44.

COVIDIEN, COVIDIEN with logo, Covidien logo and *positive results for life* are U.S. and internationally registered trademarks of Covidien AG. Other brands are trademarks of a Covidien company. ©2014 Covidien. 13-PM-0358a



6135 GUNBARREL AVENUE  
BOULDER, CO 80301  
800-635-5267

COVIDIEN.COM/RMS